Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | 2025 |
|---|---|---|
| Costs and expenses: | ||
| Cost of sales | 7,157 | 3,648 |
| Research and development | 41,725 | 36,973 |
| Selling, general, and administrative | 63,591 | 39,087 |
| Total costs and expenses | 112,473 | 79,708 |
| Loss from operations | (52,361) | (47,004) |
| Other income (expense): | ||
| Other income (expense), net | (1,704) | (644) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s SG&A?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported SG&A of $63.59M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s SG&A changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s SG&A increased by 62.7% year-over-year, from $39.09M to $63.59M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s SG&A?
- Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s SG&A has grown at a 29.9% compound annual growth rate (CAGR), from $68.49M to $194.94M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude